Summary & Overview
HCPCS A2035: Corplex/Theracor/Allacor, per milligram
HCPCS Level II code A2035 denotes billing for the pharmaceutical products Corplex p, Theracor p, or Allacor p, charged on a per-milligram basis. As a drug-supply code, it matters nationally for outpatient and ambulatory settings where precise milligram-based billing affects claims processing, cost reporting, and drug utilization monitoring. Accurate use of A2035 ensures consistent representation of unit-based medication costs across payers and settings.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. These payers commonly adjudicate drug-supply codes for outpatient infusion, clinic-administered medications, and pharmacy-dispensed specialty products.
Readers will learn the clinical and billing context for A2035, including its role as a per-milligram pharmaceutical supply code, typical sites of service where it is used, and the national payer landscape that influences coverage and claims handling. The publication addresses benchmarks, payer coverage considerations, and relevant policy updates where available. Where input data is not provided, the document notes that specific details are not available in the input.
Billing Code Overview
HCPCS Level II code A2035 describes Corplex p or Theracor p or Allacor p, per milligram. This code represents a billed charge for a pharmaceutical product measured and reported by milligram, indicating unit-based drug supply.
Service Type: Pharmaceutical product administration / drug supply
Typical Site of Service: Outpatient infusion center, clinic, or other ambulatory care setting where billed medications are provided by milligram.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing intramuscular or subcutaneous administration of a compounded biologic supplement product listed as A2035 (Corplex P, Theracor P, or Allacor P) billed per milligram. The clinical workflow begins with a clinician evaluation for indications such as documented nutritional deficiency, outpatient immunomodulatory support, or adjunct therapy for chronic inflammatory conditions when an injectable peptide or amino-acid–based supplement is clinically indicated. The prescriber writes an order specifying the compound and total milligrams required. A pharmacy compounder prepares a sterile, preservative-free dose under USP <797> conditions. The patient presents to an outpatient infusion clinic, physician office, or ambulatory surgical center where nursing staff verify the medication, perform routine preadministration assessments (vital signs, allergy review), and prepare the injection or infusion. Administration is performed by a licensed nurse; monitoring for immediate adverse reactions follows for a standard observation period. Documentation includes the product name, lot number, total milligrams administered, route, site, lot, consent, and any concurrent procedures. Billing uses A2035 reported per milligram with appropriate modifiers as required by payer policy and with linkage to the primary diagnosis ICD-10 code(s). Typical sites of service are outpatient infusion centers, physician offices, ambulatory surgical centers, and hospital outpatient departments. Typical patient scenarios include patients with documented deficiencies or conditions requiring parenteral supplementation, patients receiving adjunctive immunonutrition, or those receiving compounded peptide preparations as part of a specialty care plan.
Coding Specifications
| Modifier | Description |
|---|